Sanofi and Regeneron Announce Presentation of Positive Data from Long-Term Pivotal Phase 3 CHRONOS Study of DupixentA in Moderate-to-Severe Atopic Dermatitis Sanofi and Regeneron Announce Presentation of Positive Data from Long-Term Pivotal Phase 3 CHRONOS Study of DupixentA in Moderate-to-Severe Atopic Dermatitis Paris, France and Tarrytown, N.Y. - March 4, 2017 - Sanofi and Regeneron Pharmaceuticals, Inc. today presented detailed results from the one-year Phase 3 CHRONOS study, which showed that patients receiving the investigational drug DupixentA with topical corticosteroids achieved significantly improved measures of overall disease severity compared to TCS alone in adults with uncontrolled moderate-to-severe atopic dermatitis .
A delegation of staff and scientists from Tarrytown-based Regeneron Pharmaceuticals recently visited Ossining High School to give their congratulations to the school's three 2017 Regeneron Science Talent Search Scholars. The Regeneron Science Talent Search is the nation's oldest and most prestigious pre-college science competition and is a program of the Society for Science & the Public, according to a release from the Ossining Union Free School District.
Sanofi SA led Frances's benchmark CAC-40 lower Friday after a U.S. court barred the sale of the pharmaceutical maker's new anti-cholesterol drug Praulent until two patents held by rival Amgen Inc. expire. Sanofi, the commercial partner to Tarrytown, NY-based Regeneron Pharmaceuticals Inc. , which discovered the drug, said in a statement that the two companies consider Amgen's patents "invalid" and plan to appeal the U.S. District Court for the District of Delaware's Thursday ruling in favour of Amgen's competing drug, Repatha.
... drug Praluent until two patents held by rival Amgen (AMGN) expire. Sanofi, the commercial partner to Tarrytown, N.Y.-based Regeneron Pharmaceuticals (REGN) , which discovered the drug, said in a statement that the two companies consider Amgen's ...
Paris, France, and Tarrytown, N.Y. - December 8, 2016 - Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the European Medicines Agency has accepted for review the Marketing Authorization Application for DupixentA for the treatment of adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy. The investigational biologic therapy Dupixent inhibits signaling of IL-4 and IL-13, two key cytokines required for the type 2 immune response, which is believed to be a major driver in the pathogenesis of the disease.